Sort
261,768 grants matching “gene therapy”
Viral Replication and Interactions with Host Factors
$993,604Vinay K. Pathak · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Structure and Function of Vif and APOBEC3 (A3) Proteins
$993,604Vinay K. Pathak · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
University of California and UT Southwestern D-PDTC
$993,582Luis Guillermo Carvajal Carmona · University Of California At Davis · U54 · FY2024 · CA
Understanding how bacteriophages affect wound ecologies and developing new tools to harness bacteria-phage interactions
$993,536Irene Ann Chen · University Of California Los Angeles · DP2 · FY2016 · GM
Microphysiological systems to model vascular malformations
$993,445Christopher C. W. Hughes · University Of California-Irvine · UG3 · FY2017 · HL
NEUROTRAUMA RESEARCH CENTER
$993,340University Of Miami School Of Medicine · P50 · FY2001 · NS
Defining the genetic basis of human respiratory chain disease
$993,317Vamsi Krishna Mootha · Massachusetts General Hospital · RC2 · FY2009 · HG
Subcellular localization of nanoparticles
$993,315Mauro Ferrari · Methodist Hospital Research Institute · RC2 · FY2010 · GM
Biomarkers of ABCA1 mediated functions in Alzheimers disease
$993,303Hussein N Yassine · University Of Southern California · R01 · FY2020 · AG
Phosphoinositides and Cancer Metabolism
$993,256Lewis C Cantley · Dana-Farber Cancer Inst · R35 · FY2022 · CA
Regulation of Lymphocyte Proliferation and Replicative Capacity
$993,254Richard J. Hodes · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
STING Activators as Therapy for Cancer
$993,220Glen N Barber · Stinginn, Llc · R42 · FY2022 · CA
Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies
$993,146Morgan Chandler · Mimetas Us, Inc. · R44 · FY2023 · DK
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
$993,128Craig Gelfand · Advent Therapeutics, Inc. · R44 · FY2025 · HL
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
$993,003Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
$992,932Ozgur Sahin · Loxigen, Inc. · R42 · FY2024 · CA
SDMC: HIV Vaccine Trials Network
$992,886Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2025 · AI
Antimicrobial and Regenerative Treatment for Oral Mucositis
$992,846Shenda Baker · Synedgen, Inc. · R44 · FY2011 · DE
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.
$992,797Iain James Macleod · Aldatu Biosciences, Inc. · SB1 · FY2022 · AI
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
$992,757Peter W. Stacpoole · Medosome Biotec, Llc · R42 · FY2021 · HD
A human cytomegalovirus-based immunotherapy for HIV-1
$992,696Eric Bruening · Tomegavax, Inc. · R44 · FY2014 · AI
The Development of a Web-based Data Retrieval System for HIV Therapy Guidance
$992,666Colombe Chappey · Monogram Biosciences, Inc. · R44 · FY2007 · AI
High-throughput development and characterization of compact tools for transcriptional and chromatin perturbations
$992,642Lacramioara Bintu · Stanford University · R01 · FY2022 · HG
Gene and Cell Therapy of Duchenne Muscular Dystrophy
$992,626Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh · U54 · FY2008 · AR
Nonhuman Primate
$992,607Michael K Axthelm · Oregon Health & Science University · P01 · FY2014 · AI